With this method, used in combination with molecular docking screening and in vitro antiviral screening approaches, we identify compounds that bind to ACE2 or to the SARS-CoV-2 spike protein RBD and that block SARS-CoV-2 in vitro infection. The gene discussed is ACE2; the disease is infection.